









Challenging the Status Quo: New Androgen Deprivation Therapy (ADT) Options






*Target Audience: Urologists, medical oncologists, radio-oncologists, radiologists, cardiologists, and cardio-oncologists




Learning Gains Across Objectives: Session 1






* 4 statistically significant improvements; p<.05 comparison of pre to post and pre to 2 mos follow-up results n=255 pre; n=187 post; n=79 follow-up

Learning Gains Across Objectives: Session 2



* 3 statistically significant improvements; p<.05 comparison of pre to post and pre to 2 mos follow up results n=267 pre; n=180 post; n=79 follow-up

Learning Gains Across Objectives: Session 3



5 statistically significant improvements; p<.05 comparison of pre to post and pre to 2 mos follow up results n=318 pre; n=217 post; n=79 follow-up

Future Directions for Education

Outcomes results and participant questions suggest the value of future education regarding:

- Applicability of latest trial results to inform treatment selection
- Continuous update on application of strategies to minimize and manage cardiovascular events
- Knowledge of pharmacologic and administration differences between current LHRH agonists and GnRH antagonists
- Addressing challenges in barriers to optimizing care
- Engaging in multidisciplinary consultation and referral